Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
15.4
USD
|
+5.62%
|
|
+19.57%
|
-29.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15.26
|
64.29
|
429.5
|
1,176
|
1,145
|
982.9
|
-
|
-
|
Enterprise Value (EV)
1 |
-7.262
|
64.29
|
232.5
|
755.7
|
688.2
|
564.7
|
395.8
|
552.9
|
P/E ratio
|
-0.36
x
|
-0.53
x
|
-2.96
x
|
-7.21
x
|
-4.1
x
|
-3.5
x
|
-3.54
x
|
-5.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.42
x
|
61.2
x
|
145
x
|
663
x
|
3,648
x
|
3,202
x
|
317
x
|
6.07
x
|
EV / Revenue
|
-1.63
x
|
61.2
x
|
78.5
x
|
426
x
|
2,192
x
|
1,839
x
|
128
x
|
3.41
x
|
EV / EBITDA
|
-
|
-
|
-3.57
x
|
-5.64
x
|
-3.68
x
|
-3.85
x
|
-2.25
x
|
-2.97
x
|
EV / FCF
|
-
|
-2,155,836
x
|
-4,259,465
x
|
-7,985,907
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
3.05
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,119
|
3,908
|
21,722
|
40,248
|
52,586
|
63,822
|
-
|
-
|
Reference price
2 |
7.199
|
16.45
|
19.77
|
29.21
|
21.78
|
15.40
|
15.40
|
15.40
|
Announcement Date
|
3/11/20
|
3/26/21
|
3/10/22
|
3/8/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.461
|
1.05
|
2.963
|
1.772
|
0.314
|
0.307
|
3.097
|
161.9
|
EBITDA
1 |
-
|
-
|
-65.14
|
-134
|
-186.8
|
-146.5
|
-175.9
|
-186.1
|
EBIT
1 |
-41.98
|
-110.4
|
-79.73
|
-134.3
|
-254.4
|
-283.4
|
-312.6
|
-200.8
|
Operating Margin
|
-941.02%
|
-10,512.38%
|
-2,690.79%
|
-7,579.23%
|
-81,035.03%
|
-92,303.19%
|
-10,093.24%
|
-124%
|
Earnings before Tax (EBT)
1 |
-41.87
|
-110.7
|
-79.41
|
-129.9
|
-237.7
|
-259.9
|
-285.7
|
-156.4
|
Net income
1 |
-41.87
|
-110.7
|
-79.41
|
-129.9
|
-237.7
|
-266.4
|
-294.4
|
-191.3
|
Net margin
|
-938.65%
|
-10,544.29%
|
-2,680.16%
|
-7,329.23%
|
-75,711.46%
|
-86,774.35%
|
-9,507.39%
|
-118.12%
|
EPS
2 |
-20.10
|
-31.13
|
-6.680
|
-4.050
|
-5.310
|
-4.396
|
-4.346
|
-2.799
|
Free Cash Flow
|
-
|
-29.82
|
-54.58
|
-94.64
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-2,840.1%
|
-1,842.09%
|
-5,340.58%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/26/21
|
3/10/22
|
3/8/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.208
|
0.214
|
0.216
|
0.256
|
1.195
|
0.105
|
0.098
|
0.072
|
0.072
|
0.072
|
0.0798
|
0.0819
|
0.0799
|
0.082
|
0.036
|
EBITDA
1 |
-10.12
|
-25.56
|
-21.19
|
-24.62
|
-24.84
|
-48.97
|
-57.15
|
-46.84
|
-51.09
|
-45.28
|
-33.64
|
-35.34
|
-37.43
|
-40.13
|
-
|
EBIT
1 |
-14.13
|
-29.08
|
-25.89
|
-29.56
|
-29.78
|
-49.07
|
-72.47
|
-59.28
|
-51.22
|
-71.48
|
-67
|
-70.07
|
-71.66
|
-74.82
|
-71.25
|
Operating Margin
|
-6,795.19%
|
-13,589.25%
|
-11,985.65%
|
-11,548.44%
|
-2,492.47%
|
-46,729.52%
|
-73,952.04%
|
-82,326.39%
|
-71,144.44%
|
-99,276.39%
|
-83,933.23%
|
-85,540.16%
|
-89,663.16%
|
-91,248.29%
|
-197,927.78%
|
Earnings before Tax (EBT)
1 |
-14.04
|
-28.95
|
-25.69
|
-29.49
|
-28.9
|
-45.78
|
-68.15
|
-55.06
|
-47.66
|
-66.86
|
-61.14
|
-64.3
|
-65.58
|
-68.94
|
-66.55
|
Net income
1 |
-14.04
|
-28.95
|
-25.69
|
-29.49
|
-28.9
|
-45.78
|
-68.15
|
-55.06
|
-47.66
|
-66.86
|
-62.47
|
-65.31
|
-68.24
|
-70.04
|
-66.55
|
Net margin
|
-6,751.44%
|
-13,526.17%
|
-11,894.91%
|
-11,519.92%
|
-2,418.83%
|
-43,604.76%
|
-69,541.84%
|
-76,476.39%
|
-66,194.44%
|
-92,861.11%
|
-78,256.86%
|
-79,719.02%
|
-85,380.38%
|
-85,411.2%
|
-184,873.61%
|
EPS
2 |
-1.250
|
-1.320
|
-0.9800
|
-1.060
|
-0.8600
|
-1.130
|
-1.610
|
-1.270
|
-1.090
|
-1.350
|
-1.071
|
-1.077
|
-1.096
|
-1.107
|
-0.9400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/5/21
|
3/10/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/8/23
|
5/10/23
|
8/8/23
|
11/13/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
22.5
|
-
|
197
|
420
|
457
|
418
|
587
|
430
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-29.8
|
-54.6
|
-94.6
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
9.560
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-2.920
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.04
|
-
|
0.8
|
0.9
|
1
|
1
|
1
|
Capex / Sales
|
-
|
4%
|
-
|
44.98%
|
285.99%
|
325.73%
|
32.29%
|
0.62%
|
Announcement Date
|
3/11/20
|
3/26/21
|
3/10/22
|
3/8/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
15.4
USD Average target price
39.36
USD Spread / Average Target +155.57% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.29% | 983M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +28.07% | 12.14B | | +0.17% | 12.15B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|